# Michele Maio

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michele-maio/

## Facts

| Field | Value |
| --- | --- |
| Citations | 85,228 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 99 |
| i10-index | 307 |
| Last Known Institution | University of Siena |
| OpenAlex ID | https://openalex.org/A5018536695 |
| ORCID iD | https://orcid.org/0000-0002-0323-6321 |
| Works | 843 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study](https://scholariq.org/papers/pembrolizumab-in-patients-with-microsatellite-instability-high-advanced/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [University of Siena](https://scholariq.org/institutions/university-of-siena/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.